A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma
This is an open-label, multicenter Phase Ib study designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of SGN-40 when combined with rituximab in patients with relapsed CD20-positive, follicular or marginal zone NHL who have received at least one prior rituximab-containing regimen.
Non-Hodgkin's Lymphoma
DRUG: rituximab|DRUG: SGN-40
Incidence and nature of dose-limiting toxicities in order to determine the maximum tolerated dose, Length of study
Changes in vital signs, physical examination findings, and clinical laboratory results, Length of study|Incidence, nature, and severity of adverse events, Length of study|Pharmacokinetic parameters, Length of study|Patient's best response as assessed by the investigator, Length of study|Duration of response, Length of study|Event-free survival, Length of study
This is an open-label, multicenter Phase Ib study designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of SGN-40 when combined with rituximab in patients with relapsed CD20-positive, follicular or marginal zone NHL who have received at least one prior rituximab-containing regimen.